Pharmacodynamics of Vancomycin and Other Antimicr Staphylococcus aureus Lower Respiratory Tract Infecti

Clinical Pharmacokinetics

43, 925-942

DOI: 10.2165/00003088-200443130-00005

Citation Report

#	Article	IF	Citations
2	Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection. Expert Review of Anti-Infective Therapy, 2006, 4, 479-490.	2.0	49
3	The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin. Clinical Infectious Diseases, 2006, 42, S35-S39.	2.9	610
4	Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opinion on Pharmacotherapy, 2006, 7, 1555-1569.	0.9	26
5	Optimal Therapy for Methicillin-Resistant Staphylococcus aureus Pneumonia. Chest, 2006, 130, 938-940.	0.4	21
6	Evaluation of Clinical Efficacy of Maedaâ€™s Nomogram for Vancomycin Dosage Adjustment in Adult Japanese MRSA Pneumonia Patients. Drug Metabolism and Pharmacokinetics, 2006, 21, 54-60.	1.1	8
8	Predictors of Mortality for Methicillin-Resistant Staphylococcus aureus Health-Careâ€“Associated Pneumonia. Chest, 2006, 130, 947-955.	0.4	237
9	Optimizing Antibiotic Treatment for Ventilator-Associated Pneumonia. Pharmacotherapy, 2006, 26, 204-213.	1.2	27
10	Potential Impact of Vancomycin Pulmonary Distribution on Treatment Outcomes in Patients with Methicillin-ResistantStaphylococcus aureusPneumonia. Pharmacotherapy, 2006, 26, 539-550.	1.2	68
11	The Role of Vancomycin in the Treatment Paradigm. Clinical Infectious Diseases, 2006, 42, S51-S57.	2.9	149
12	High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections. Archives of Internal Medicine, 2006, 166, 2138.	4.3	777
13	Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 2006, 58, 1177-1184.	1.3	100
14	Corticosteroids in ARDS. New England Journal of Medicine, 2006, 355, 316-319.	13.9	5
15	Counterpoint: Vancomycin and Staphylococcus aureus--An Antibiotic Enters Obsolescence. Clinical Infectious Diseases, 2007, 44, 1543-1548.	2.9	166
16	Vancomycin for treatment of invasive, multi-drug resistantStaphylococcus aureusinfections. Expert Opinion on Pharmacotherapy, 2007, 8, 1245-1261.	0.9	9
17	Appropriate Pharmacokinetic Index for Outcome in Staphylococcus aureus Pneumonia. Chest, 2007, 132, 1101-1102.	0.4	5
18	Corticosteroids in ARDS. Chest, 2007, 132, 1093-1094.	0.4	17
19	Optimizing Therapy for MRSA Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 615-623.	0.8	7
20	Observations on vancomycin use in U.S. hospitals. American Journal of Health-System Pharmacy, 2007, 64, 1633-1641.	0.5	17

#	Article	IF	Citations
21	Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05. Journal of Antimicrobial Chemotherapy, 2007, 60, 788-794.	1.3	385
22	Setting and Revising Antibacterial Susceptibility Breakpoints. Clinical Microbiology Reviews, 2007, 20, 391-408.	5.7	455
23	Appropriate Pharmacokinetic Index for Outcome in Staphylococcus aureus Pneumonia. Chest, 2007, 132, 1102-1103.	0.4	3
25	Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections. Expert Review of Anti-Infective Therapy, 2007, 5, 255-270.	2.0	17
26	Vancomycin: does it still have a role as an antistaphylococcal agent?. Expert Review of Anti-Infective Therapy, 2007, 5, 393-401.	2.0	37
27	Update on prevalence and treatment of methicillin-resistantStaphylococcus aureusinfections. Expert Review of Anti-Infective Therapy, 2007, 5, 961-981.	2.0	39
28	Vancomycin In Vitro Bactericidal Activity and Its Relationship to Efficacy in Clearance of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2007, 51, 2582-2586.	1.4	215
29	Pharmacokinetic and Pharmacodynamic Aspects of Antibiotic Use in High-Risk Populations. Infectious Disease Clinics of North America, 2007, 21, 821-846.	1.9	27
30	Point: Vancomycin Is Not Obsolete for the Treatment of Infection Caused by Methicillin-Resistant Staphylococcus aureus. Clinical Infectious Diseases, 2007, 44, 1536-1542.	2.9	163
31	Infectious Diseases: Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus. Annals of Pharmacotherapy, 2007, 41, 235-244.	0.9	49
32	MRSA bacteraemia. International Journal of Antimicrobial Agents, 2007, 30, 66-70.	1.1	36
33	Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance. Brazilian Journal of Microbiology, 2007, 38, 183-193.	0.8	10
34	Emerging Options for Treatment of Invasive, Multidrug-ResistantStaphylococcus aureusInfections. Pharmacotherapy, 2007, 27, 227-249.	1.2	99
36	Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Medicine, 2007, 33, 279-285.	3.9	147
37	Population pharmacokinetic and pharmacodynamic modeling of norvancomycin. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 275-284.	1.3	10
38	Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clinical Microbiology and Infection, 2008, 14, 116-123.	2.8	53
41	Should the Currently Recommended Twice-DailyÂDosingÂStillÂbeÂConsidered theÂMostÂAppropriateÂRegimenÂfor TreatingÂMRSAÂVentilator-Associated PneumoniaÂwithÂVancomycin?. Clinical Pharmacokinetics, 2008, 47, 147-152.	1.6	28
42	Glycopeptide Bone Penetration in Patients with Septic Pseudoarthrosis of the Tibia. Clinical Pharmacokinetics, 2008, 47, 793-805.	1.6	36

#	Article	IF	Citations
44	Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. International Journal of Antimicrobial Agents, 2008, 31, 1-9.	1.1	72
45	Current challenges in treating MRSA: what are the options?. Expert Review of Anti-Infective Therapy, 2008, 6, 601-618.	2.0	13
46	Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. Expert Review of Anti-Infective Therapy, 2008, 6, 83-99.	2.0	15
47	Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity. American Journal of Medicine, 2008, 121, 515-518.	0.6	61
49	An Update on the Management of Nosocomial Pneumonia. Journal of Pharmacy Practice, 2008, 21, 380-389.	0.5	1
50	Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimens. International Journal of Antimicrobial Agents, 2008, 32, 294-301.e7.	1.1	87
51	Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infectious Diseases, The, 2008, 8, 612-620.	4.6	80
52	Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia. Clinical Infectious Diseases, 2008, 46, 193-200.	2.9	719
53	Vancomycin MICs for Methicillin-Resistant Staphylococcus aureus Isolates Differ Based upon the Susceptibility Test Method Used. Antimicrobial Agents and Chemotherapy, 2008, 52, 4528-4528.	1.4	104
54	Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity. Antimicrobial Agents and Chemotherapy, 2008, 52, 1330-1336.	1.4	519
55	Increasing Antibiotic Resistance among Methicillinâ€ResistantStaphylococcus aureusStrains. Clinical Infectious Diseases, 2008, 46, S360-S367.	2.9	227
57	Review: Novel targets in the management of pneumonia. Therapeutic Advances in Respiratory Disease, 2008, 2, 387-400.	1.0	8
58	Pharmacokineticâ€Pharmacodynamic Modeling of Dalbavancin, a Novel Glycopeptide Antibiotic. Journal of Clinical Pharmacology, 2008, 48, 1063-1068.	1.0	43
60	Clinical Practice Guidelines for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 19-53.	0.7	203
61	Current and novel antibiotics against resistant Gram-positive bacteria. Infection and Drug Resistance, 2008, 1, 27.	1.1	30
62	Therapeutic Drug Monitoring (TDM) of Antimicrobial Agents. Infection and Chemotherapy, 2008, 40, 133.	1.0	4
63	Vancomycin Continuous Infusion as Prophylaxis for Vascular Surgery. Therapeutic Drug Monitoring, 2009, 31, 786-788.	1.0	5
64	Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2009, 53, 3162-3165.	1.4	87

#	Article	IF	Citations
65	Is Vancomycin Ototoxicity a Significant Risk?. Antimicrobial Agents and Chemotherapy, 2009, 53, 4572-4573.	1.4	13
66	Prospectively Validated Dosing Nomograms for Maximizing the Pharmacodynamics of Vancomycin Administered by Continuous Infusion in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2009, 53, 1863-1867.	1.4	113
67	Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia. Antimicrobial Agents and Chemotherapy, 2009, 53, 3894-3901.	1.4	49
68	Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2009, 53, 805-807.	1.4	29
70	Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing Doses. Antimicrobial Agents and Chemotherapy, 2009, 53, 483-486.	1.4	100
71	Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type. Journal of Clinical Pharmacy and Therapeutics, 2009, 34, 473-483.	0.7	68
72	Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. Journal of Antimicrobial Chemotherapy, 2009, 63, 1050-1057.	1.3	124
74	Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. International Journal of Antimicrobial Agents, 2009, 34, 555-560.	1.1	55
75	Risk factors and management of Gram-positive bacteraemia. International Journal of Antimicrobial Agents, 2009, 34, S26-S30.	1.1	40
76	Antibiotic therapy of vascular catheter-related bloodstream infections: is vancomycin the optimal choice for Staphylococcus aureus infections?. International Journal of Antimicrobial Agents, 2009, 34, S43-S46.	1.1	3
77	Vancomycin Dosage Optimization in Patients with Malignant Haematological Disease by Pharmacokinetic/Pharmacodynamic Analysis. Clinical Pharmacokinetics, 2009, 48, 273-280.	1.6	27
78	Pharmacokinetic and Pharmacodynamic Parameters of Antimicrobials. Clinical Pharmacokinetics, 2009, 48, 517-528.	1.6	38
79	Effect of linezolid in ventilator-associated pneumonia caused by MRSA. Expert Review of Anti-Infective Therapy, 2009, 7, 183-188.	2.0	1
80	Vancomycin in Combination with Other Antibiotics for the Treatment of Serious Methicillinâ€ResistantStaphylococcus aureusInfections. Clinical Infectious Diseases, 2009, 49, 1072-1079.	2.9	131
81	Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 475-487.	1.5	30
82	Appropriate use of antimicrobials: the peculiarity of septic patients. International Journal of Antimicrobial Agents, 2009, 34, S52-S54.	1.1	4
83	Pharmacokinetics and Pharmacodynamics of Antibacterial Agents. Infectious Disease Clinics of North America, 2009, 23, 791-815.	1.9	387
84	Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. Current Opinion in Infectious Diseases, 2009, 22, 525-534.	1.3	32

#	Article	IF	Citations
85	Prevalence of Methicillin-Resistant Staphylococcus aureus Strains With Vancomycin Minimum Inhibitory Concentration 2 Î¼g/mL in New York City Area Hospitals and Implications on Pharmacodynamic Target Attainment. Infectious Diseases in Clinical Practice, 2009, 17, 95-98.	0.1	1
86	A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data. Biological and Pharmaceutical Bulletin, 2009, 32, 99-104.	0.6	21
87	Optimizing Vancomycin Dosing through Pharmacodynamic Assessment Targeting Area under the Concentration-Time Curve/Minimum Inhibitory Concentration. Hospital Pharmacy, 2009, 44, 751-765.	0.4	49
88	Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant Staphylococcus aureus Infections Is Inadequate. Pediatric Infectious Disease Journal, 2009, 28, 398-402.	1.1	135
89	Vancomycin Dosing for Pneumonia in Critically Ill Trauma Patients. Journal of Trauma, 2009, 67, 802-804.	2.3	18
90	Optimizing Antibiotic Use in the Intensive Care Unit. Clinical Pulmonary Medicine, 2010, 17, 162-169.	0.3	1
91	Use of Vancomycin in Pediatrics. Pediatric Infectious Disease Journal, 2010, 29, 462-464.	1.1	33
92	Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. European Journal of Medical Research, 2010, 15, 533.	0.9	65
93	The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 1475-1479.	1.3	25
94	Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: A Monte Carlo simulation. Clinical Therapeutics, 2010, 32, 534-542.	1.1	47
95	Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. Journal of Infection, 2010, 60, 140-145.	1.7	70
96	Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. British Journal of Clinical Pharmacology, 2010, 70, 201-212.	1.1	91
97	Initial Vancomycin Dosing Recommendations for Critically Ill Patients Undergoing Continuous Venovenous Hemodialysis. Canadian Journal of Hospital Pharmacy, 2010, 63, 196-206.	0.1	17
98	Treatment of Methicillin-Resistant Staphylococcus Aureus with a Vancomycin Minimum Inhibitory Concentration of 2 mcg/mL. Hospital Pharmacy, 2010, 45, 375-380.	0.4	3
99	A survey of attitudes towards methicillin-resistant Staphylococcus aureus bacteraemias amongst United Kingdom microbiologists. Journal of Antimicrobial Chemotherapy, 2010, 65, 347-349.	1.3	7
100	Population Pharmacokinetics of Vancomycin in Premature Malaysian Neonates: Identification of Predictors for Dosing Determination. Antimicrobial Agents and Chemotherapy, 2010, 54, 2626-2632.	1.4	54
101	Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs. Journal of Antimicrobial Chemotherapy, 2010, 65, 1784-1791.	1.3	26
102	Continuing Education: Alternative Approaches to Optimizing Antimicrobial Pharmacodynamics in Critically Ill Patients. Journal of Pharmacy Practice, 2010, 23, 6-18.	0.5	7

#	Article	IF	Citations
103	Vancomycin Pharmacokinetics and Pharmacodynamics during Short Daily Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1981-1987.	2.2	16
104	Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications. Clinical Microbiology Reviews, 2010, 23, 99-139.	5.7	804
105	Population Pharmacokinetic Analysis of Vancomycin Using Serum Cystatin C as a Marker of Renal Function. Antimicrobial Agents and Chemotherapy, 2010, 54, 778-782.	1.4	56
106	ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiology, 2010, 5, 1765-1773.	1.0	13
107	Resistant pathogen-associated skin and skin-structure infections: antibiotic options. Expert Review of Anti-Infective Therapy, 2010, 8, 1019-1036.	2.0	8
108	Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. International Journal of Antimicrobial Agents, 2010, 35, 431-438.	1.1	57
109	Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia. International Journal of Antimicrobial Agents, 2010, 36, S33-S39.	1.1	14
110	Augmented Renal Clearance. Clinical Pharmacokinetics, 2010, 49, 1-16.	1.6	313
111	Recent changes in vancomycin use in renal failure. Kidney International, 2010, 77, 760-764.	2.6	84
112	Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagnostic Microbiology and Infectious Disease, 2010, 67, 228-233.	0.8	60
113	Consensus document on controversial issues for the treatment of hospital-associated pneumonia. International Journal of Infectious Diseases, 2010, 14, S55-S65.	1.5	5
114	The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Current Medical Research and Opinion, 2010, 26, 571-588.	0.9	110
115	Use of vancomycin pharmacokineticâ€“pharmacodynamic properties in the treatment of MRSA infections. Expert Review of Anti-Infective Therapy, 2010, 8, 95-106.	2.0	67
116	Penetration of Vancomycin into Epithelial Lining Fluid in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2011, 55, 5507-5511.	1.4	51
117	Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization. Antimicrobial Agents and Chemotherapy, 2011, 55, 4619-4630.	1.4	198
118	Preparation of liposomal vancomycin and intracellular killing of meticillin-resistant Staphylococcus aureus (MRSA). International Journal of Antimicrobial Agents, 2011, 37, 140-144.	1.1	81
119	Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?. International Journal of Antimicrobial Agents, 2011, 37, 202-209.	1.1	59
120	Optimizing Antibiotic Pharmacodynamics in Hospital-acquired and Ventilator-acquired Bacterial Pneumonia. Clinics in Chest Medicine, 2011, 32, 439-450.	0.8	7

#	Article	IF	Citations
121	Pharmacokinetics and Pharmacodynamics: Optimal Antimicrobial Therapy in the Intensive Care Unit. Critical Care Clinics, 2011, 27, 1-18.	1.0	46
122	Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clinical Infectious Diseases, 2011, 52, e18-e55.	2.9	2,673
123	Optimizing initial vancomycin dosing in burn patients. Burns, 2011, 37, 406-414.	1.1	23
124	Optimal Dose of Vancomycin for Treating Methicillin-Resistant Staphylococcus Aureus Pneumonia in Critically Ill Patients. Anaesthesia and Intensive Care, 2011, 39, 1030-1037.	0.2	31
125	Development of Software for Antimicrobial PK/PD Simulation incorporating Montecarlo Simulation Based on Microsoft^|^reg; Office Excel. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.1	0
126	FarmacocinÃ©tica y farmacodinamia de antimicrobianos: a propÃ³sito de pacientes con neutropenia y fiebre. Revista Chilena De Infectologia, 2011, 28, 537-545.	0.0	5
127	Teicoplanin Dosing Strategy for Treatment ofStaphylococcus aureusin Korean Patients with Neutropenic Fever. Yonsei Medical Journal, 2011, 52, 616.	0.9	16
128	Clinical Pharmacology of Anti-Infective Drugs. , 2011, , 1160-1211.		7
129	Antimicrobial therapy. , 0, , 963-986.		0
130	Vancomycin pharmacokineticâ€“pharmacodynamic parameters to optimize dosage administration in critically ill children. Pediatric Critical Care Medicine, 2011, 12, e250-e254.	0.2	33
132	Vancomycin Dosing in Patients on Intermittent Hemodialysis. Seminars in Dialysis, 2011, 24, 50-55.	0.7	39
133	Impact of a Hospitalwide Increase in Empiric Pediatric Vancomycin Dosing on Initial Trough Concentrations. Pharmacotherapy, 2011, 31, 871-876.	1.2	42
134	Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy, 2011, 66, 2386-2392.	1.3	65
135	Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Medicine, 2011, 37, 639-647.	3.9	72
136	Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Annals of Intensive Care, 2011, 1, 26.	2.2	44
137	Vancomycin dosing and monitoring 2 years after the guidelines. Expert Review of Anti-Infective Therapy, 2011, 9, 657-667.	2.0	20
138	Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units. Journal of Antimicrobial Chemotherapy, 2011, 66, 2647-2650.	1.3	52
139	Reply: Outcomes Associated with AUC₂₄/MIC Nomogram Dosing of Vancomycin. Annals of Pharmacotherapy, 2011, 45, 1314-1315.	0.9	0

#	Article	IF	Citations
140	Implementation of a Dose Calculator for Vancomycin to Achieve Target Trough Levels of 15-20 Âg/mL in Persons Undergoing Hemodialysis. Clinical Infectious Diseases, 2011, 53, 124-129.	2.9	29
141	Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding. Antimicrobial Agents and Chemotherapy, 2011, 55, 4277-4282.	1.4	69
142	Vancomycin: We Can't Get There From Here. Clinical Infectious Diseases, 2011, 52, 969-974.	2.9	214
143	Weight-Based Loading of Vancomycin in Patients on Hemodialysis. Clinical Infectious Diseases, 2011, 53, 164-166.	2.9	23
144	PEGylated Liposome Encapsulation Increases the Lung Tissue Concentration of Vancomycin. Antimicrobial Agents and Chemotherapy, 2011, 55, 4537-4542.	1.4	62
145	In Vitro Activities of Daptomycin-, Vancomycin-, and Teicoplanin-Loaded Polymethylmethacrylate against Methicillin-Susceptible, Methicillin-Resistant, and Vancomycin-Intermediate Strains of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2011, 55, 5480-5484.	1.4	65
146	Comment: Outcomes Associated with AUC24/MIC Nomogram Dosing of Vancomycin. Annals of Pharmacotherapy, 2011, 45, 1313-1314.	0.9	1
147	Outcomes Associated with AUC₂₄/MIC Nomogram Dosing of Vancomycin. Annals of Pharmacotherapy, 2011, 45, 687-689.	0.9	9
148	Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial. Antimicrobial Agents and Chemotherapy, 2011, 55, 5475-5479.	1.4	213
149	Preferential Emergence of Reduced Vancomycin Susceptibility in Health Care-Associated Methicillin-Resistant Staphylococcus aureus Isolates during Continuous-Infusion Vancomycin Therapy in an In Vitro Dynamic Model. Antimicrobial Agents and Chemotherapy, 2011, 55, 3627-3630.	1.4	11
150	Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens. Antimicrobial Agents and Chemotherapy, 2011, 55, 2704-2709.	1.4	197
151	Clinical Outcomes of Linezolid vs Vancomycin in Methicillin-Resistant Staphylococcus aureus Ventilator-Associated Pneumonia. Journal of Intensive Care Medicine, 2011, 26, 385-391.	1.3	26
152	Vancomycin Dosing: Assessment of Time to Therapeutic Concentration and Predictive Accuracy of Pharmacokinetic Modeling Software. Annals of Pharmacotherapy, 2011, 45, 757-763.	0.9	53
153	Vancomycin MICs do not predict the outcome of methicillin-resistant Staphylococcus aureus bloodstream infections in correctly treated patients. Journal of Antimicrobial Chemotherapy, 2012, 67, 1760-1768.	1.3	42
154	Methicillin-Resistant Staphylococcus aureus and Vancomycin: Minimum Inhibitory Concentration Matters. Clinical Infectious Diseases, 2012, 54, 772-774.	2.9	11
155	Dosing of antibiotics in obesity. Current Opinion in Infectious Diseases, 2012, 25, 634-649.	1.3	130
156	Serum Vancomycin Levels Resulting From Continuous or Intermittent Infusion in Critically Ill Burn Patients With or Without Continuous Renal Replacement Therapy. Journal of Burn Care and Research, 2012, 33, e254-e262.	0.2	38
157	Influence of Erroneous Patient Records on Population Pharmacokinetic Modeling and Individual Bayesian Estimation. Therapeutic Drug Monitoring, 2012, 34, 526-534.	1.0	10

#	Article	IF	Citations
158	Linezolid for the Treatment of Nosocomial Pneumonia Due to Methicillin-Resistant Staphylococcus aureus. Clinical Infectious Diseases, 2012, 55, 160-161.	2.9	13
159	Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. Journal of Antimicrobial Chemotherapy, 2012, 67, 2970-2973.	1.3	22
160	In Vitro Pharmacodynamics of Vancomycin and Cefazolin Alone and in Combination against Methicillin-Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2012, 56, 202-207.	1.4	58
161	Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant <i>Staphylococcus aureus </i>Pneumonia. Chemotherapy, 2012, 58, 308-312.	0.8	100
162	Initial Vancomycin Dosing Protocol to Achieve Therapeutic Serum Concentrations in Patients Undergoing Hemodialysis. Clinical Infectious Diseases, 2012, 55, 527-533.	2.9	30
163	Development and Stability Studies of Novel Liposomal Vancomycin Formulations. ISRN Pharmaceutics, 2012, 2012, 1-8.	1.0	41
164	Evaluation of Once-Daily Vancomycin against Methicillin-Resistant Staphylococcus aureus in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 682-686.	1.4	33
165	Gentamicin Pharmacokinetics and Pharmacodynamics during Short-Daily Hemodialysis. American Journal of Nephrology, 2012, 36, 144-150.	1.4	14
166	Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy. Critical Care Medicine, 2012, 40, 1523-1528.	0.4	185
167	Clinical pharmacokinetics of vancomycin in the neonate: a review. Clinics, 2012, 67, 831-837.	0.6	56
168	DEVELOPMENT AND VALIDATION OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD TO DETERMINE VANCOMYCIN CONCENTRATIONS IN PLASMA AND PIG PULMONARY TISSUE. Journal of Liquid Chromatography and Related Technologies, 2012, 35, 240-257.	0.5	1
169	Coagulase-negative Staphylococcus bacteraemia accounts for one third of Staphylococcus bacteraemia in a French university hospital. Scandinavian Journal of Infectious Diseases, 2012, 44, 79-85.	1.5	8
170	Guidelines for the Monitoring of Vancomycin, Aminoglycosides and Certain Antibiotics. , 2012, , 197-218.		9
171	The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2012, 54, 755-771.	2.9	457
172	Management of Antimicrobial Use in the Intensive Care Unit. Drugs, 2012, 72, 447-470.	4.9	21
173	Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 3367-3374.	1.3	13
175	Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients. International Journal of Antimicrobial Agents, 2012, 39, 332-337.	1.1	59
176	Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Annals of Intensive Care, 2012, 2, 35.	2.2	149

#	Article	IF	Citations
177	Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?. Annals of Intensive Care, 2012, 2, 22.	2.2	41
178	Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (â€˜the MIC Creepâ€™): implications for therapy. F1000 Medicine Reports, 2012, 4, 4.	2.9	90
179	A Multicenter Study of Therapeutic Drug Monitoring and Clinical Response for Anti-Methicillin-resistant Staphylococcus Aureus Agents. Iryo Yakugaku (Japanese Journal of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 657 T		
180	Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2012, 67, 17-24.	1.3	177
181	Importance of High Creatinine Clearance for Antibacterial Treatment in Sepsis. , 2012, , 171-197.		0
182	Improving Outcomes in Sepsis and Septic Shock: Getting it Right the First Time. , 2012, , 219-235.		0
183	Performance of a vancomycin dosage regimen developed for obese patients. American Journal of Health-System Pharmacy, 2012, 69, 944-950.	0.5	45
184	Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. Journal of Hospital Medicine, 2012, 7, 91-97.	0.7	31
185	Vancomycin AUC ₂₄ /MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus and Its Association with Attributable Mortality during Hospitalization. Antimicrobial Agents and Chemotherapy, 2012, 56, 634-638.	1.4	99
186	Therapeutic drug monitoring of antimicrobials. British Journal of Clinical Pharmacology, 2012, 73, 27-36.	1.1	263
188	Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing. Intensive Care Medicine, 2013, 39, 1322-1324.	3.9	13
189	Dose modulation: A new concept of antibiotic therapy in the critically ill patient?. Journal of Critical Care, 2013, 28, 341-346.	1.0	23
190	Emergency Department and Inpatient Community-Acquired Pneumonia: Practical Decision Making and Management Issues. Current Emergency and Hospital Medicine Reports, 2013, 1, 172-180.	0.6	0
191	Antimicrobial Treatment of Febrile Neutropenia: Pharmacokineticâ€“Pharmacodynamic Considerations. Clinical Pharmacokinetics, 2013, 52, 869-883.	1.6	16
192	Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs. Pharmacological Reviews, 2013, 65, 1053-1090.	7.1	248
193	The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. Journal of Antimicrobial Chemotherapy, 2013, 68, 743-748.	1.3	64
194	Vancomycin Dosing in Children and Young Adults: Back to the Drawing Board. Pharmacotherapy, 2013, 33, 1278-1287.	1.2	24
195	Methicillin-Resistant Staphylococcus aureus Infections. Medical Clinics of North America, 2013, 97, 601-619.	1.1	37

#	Article	IF	Citations
196	Systematic Review and Meta-Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter. Antimicrobial Agents and Chemotherapy, 2013, 57, 734-744.	1.4	492
198	Traitement des infections sÃ©vÃ¨res Ã Staphylococcus aureus mÃ©ticilline rÃ©sistant en rÃ©animation. Quelle antibiothÃ©rapie proposer en 2013Â?. Journal Des Anti-infectieux, 2013, 15, 47-59.	0.1	1
199	A Stewardship Programâ€™s Retrospective Evaluation of Vancomycin AUC24/MIC and Time to Microbiological Clearance in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis. Clinical Therapeutics, 2013, 35, 772-779.	1.1	64
200	Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Seminars in Fetal and Neonatal Medicine, 2013, 18, 28-34.	1.1	59
201	Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. International Journal of Antimicrobial Agents, 2013, 41, 255-260.	1.1	99
202	Impact of Weight on Treatment Efficacy and Safety in Complicated Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus. Clinical Therapeutics, 2013, 35, 1557-1570.	1.1	18
203	Development of HPLC Methods for the Determination of Vancomycin in Human Plasma, Mouse Serum and Bronchoalveolar Lavage Fluid. Journal of Chromatographic Science, 2013, 51, 201-207.	0.7	45
204	Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion. International Journal of Antimicrobial Agents, 2013, 41, 434-438.	1.1	35
205	Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. International Journal of Antimicrobial Agents, 2013, 41, 439-446.	1.1	40
206	Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Medicine, 2013, 39, 1247-1252.	3.9	68
207	Objectifs pharmacocinÃ©tiques, pharmacodynamiques (PK/PD) et adaptation posologique des antibiotiques chez le patient de rÃ©animation : vers une approche pratique. RÃ©fÃ©rences En RÃ©animation, 2013, , 83-103.	0.0	0
208	Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Journal of Infection and Chemotherapy, 2013, 19, 365-380.	0.8	145
209	Treatment of bacteraemia: meticillin-resistant Staphylococcus aureus (MRSA) to vancomycin-resistant S. aureus (VRSA). International Journal of Antimicrobial Agents, 2013, 42, S17-S21.	1.1	48
210	Review of Continuous-Infusion Vancomycin. Annals of Pharmacotherapy, 2013, 47, 219-227.	0.9	38
211	Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs in Intensive Care Unit Patients. Shock, 2013, 39, 24-28.	1.0	9
212	Vancomycin Dosing Practices, Trough Concentrations, and Predicted Area Under the Curve in Children With Suspected Invasive Staphylococcal Infections. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 259-262.	0.6	45
213	A Trial of Discontinuation of Empiric Vancomycin Therapy in Patients with Suspected Methicillin-Resistant Staphylococcus aureus Health Care-Associated Pneumonia. Antimicrobial Agents and Chemotherapy, 2013, 57, 1163-1168.	1.4	44
214	Rapid testing for methicillin-resistant Staphylococcus aureus: Implications for antimicrobial stewardship. American Journal of Health-System Pharmacy, 2013, 70, 335-342.	0.5	16

#	Article	IF	Citations
215	A Randomized Controlled Trial of a Vancomycin Loading Dose in Children. Pediatric Infectious Disease Journal, 2013, 32, 1217-1223.	1.1	23
216	Effects of Aggregate and Individual Antibiotic Exposure on Vancomycin MICs for Staphylococcus aureus Isolates Recovered from Pediatric Patients. Journal of Clinical Microbiology, 2013, 51, 2837-2842.	1.8	4
217	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection. Antimicrobial Agents and Chemotherapy, 2013, 57, 4252-4259.	1.4	68
218	Inoculum Effects of Ceftobiprole, Daptomycin, Linezolid, and Vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at Inocula of 10 ⁵ and 10 ⁷ CFU Injected into Opposite Thighs of Neutropenic Mice. Antimicrobial Agents and Chemotherapy, 2013, 57, 1434-1441.	1.4	48
219	Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. Journal of Neurosurgery, 2013, 118, 297-301.	0.9	38
220	External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. British Journal of Clinical Pharmacology, 2013, 75, 1068-1080.	1.1	92
221	A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2859-2865.	1.3	52
222	The Effect of Age and Weight on Vancomycin Serum Trough Concentrations in Pediatric Patients. Pharmacotherapy, 2013, 33, 1264-1272.	1.2	37
223	Is It Time to Replace Vancomycin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections?. Clinical Infectious Diseases, 2013, 56, 1779-1788.	2.9	105
224	Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2013, 57, 1654-1663.	1.4	176
225	Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Archives of Disease in Childhood, 2013, 98, 449-453.	1.0	104
226	Evaluation of the Relationship Between Elevated Vancomycin Trough Concentrations and Increased Efficacy and/or Toxicity. Journal of Burn Care and Research, 2013, 34, e1-e9.	0.2	11
227	Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections. Pediatric Infectious Disease Journal, 2013, 32, 1077-1079.	1.1	119
228	Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clinical Interventions in Aging, 2013, 8, 1015.	1.3	24
229	Interpretation of Epithelial Lining Fluid Concentrations of Antibiotics against Methicillin ResistantStaphylococcus aureus. Infection and Chemotherapy, 2014, 46, 219.	1.0	20
230	Vancomycin Revisited Ã¢â‚¬â€œ 60 Years Later. Frontiers in Public Health, 2014, 2, 217.	1.3	121
232	A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?. Current Drug Metabolism, 2014, 15, 581-598.	0.7	52
233	Evaluation of a Once-Daily Vancomycin Regimen in an Outpatient Leukemia/Bone Marrow Transplant Clinic (OD-VANCO Study). Canadian Journal of Hospital Pharmacy, 2014, 67, 280-5.	0.1	2

#	Article	IF	Citations
234	Underestimation of the Calculated Area Under the Concentration-Time Curve Based on Serum Creatinine for Vancomycin Dosing. Infection and Chemotherapy, 2014, 46, 21.	1.0	15
235	Estimation of Glomerular Filtration Rate to Adjust Vancomycin Dosage in Critically Ill Patients: Superiority of the Chronic Kidney Disease Epidemiology Collaboration Equation?. Anaesthesia and Intensive Care, 2014, 42, 178-184.	0.2	19
236	Implementation of vancomycin dosing nomogram in an electronic prescribing system: an innovative tool in antibiotic stewardship. Brazilian Journal of Pharmaceutical Sciences, 2014, 50, 567-572.	1.2	4
237	How to treat VAP due to MDR pathogens in ICU patients. BMC Infectious Diseases, 2014, 14, 135.	1.3	30
238	A Proposal of a Pharmacokinetic/pharmacodynamic (PK/PD) Index Map for Selecting an Optimal PK/PD Index from Conventional Indices (AUC/MIC, Cmax/MIC, and TAM) for Antibiotics. Drug Metabolism and Pharmacokinetics, 2014, 29, 455-462.	1.1	14
239	Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety. Therapeutic Advances in Drug Safety, 2014, 5, 118-120.	1.0	5
240	Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach. European Journal of Clinical Pharmacology, 2014, 70, 1353-1359.	0.8	4
242	Vancomycin Cerebrospinal Fluid Pharmacokinetics in Children with Cerebral Ventricular Shunt Infections. Pediatric Infectious Disease Journal, 2014, 33, e270-e272.	1.1	9
243	Neonatal Vancomycin Continuous Infusion. Pediatric Infectious Disease Journal, 2014, 33, 600-605.	1.1	24
244	Vancomycin Monitoring in Children Using Bayesian Estimation. Therapeutic Drug Monitoring, 2014, 36, 510-518.	1.0	35
245	An alternate pathophysiologic paradigm of sepsis and septic shock. Virulence, 2014, 5, 80-97.	1.8	73
246	Glycopeptides. , 2014, , 279-322.		0
247	Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8331-8338.	3.3	111
248	How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. Diagnostic Microbiology and Infectious Disease, 2014, 79, 441-447.	0.8	56
249	Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease. Antimicrobial Agents and Chemotherapy, 2014, 58, 3191-3199.	1.4	62
250	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infectious Diseases, The, 2014, 14, 498-509.	4.6	745
251	Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unitâ€isolated methicillinâ€resistant StaphylococcusÂaureus. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 437-443.	0.9	26
252	Simultaneous determination of seven Î²-lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 960, 134-144.	1.2	82

#	Article	IF	Citations
253	Vancomycin Exposure in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections: How Much Is Enough?. Clinical Infectious Diseases, 2014, 59, 666-675.	2.9	139
254	Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. International Journal of Antimicrobial Agents, 2014, 43, 223-230.	1.1	63
255	Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?. Antimicrobial Agents and Chemotherapy, 2014, 58, 309-316.	1.4	314
256	Which antibiotic for resistant Gram-positives, and why?. Journal of Infection, 2014, 68, S63-S75.	1.7	22
257	Area under the concentrationâ€“time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. International Journal of Antimicrobial Agents, 2014, 43, 179-183.	1.1	84
258	Impact of source of infection and vancomycin AUC0â€“24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clinical Microbiology and Infection, 2014, 20, O1098-O1105.	2.8	40
260	Therapeutic Options for Resistant Gram Positives. Current Treatment Options in Infectious Diseases, 2014, 6, 439-455.	0.8	0
261	Vancomycin Pharmacokinetic and Pharmacodynamic Models for Critically Ill Patients with Post-Sternotomy Mediastinitis. Clinical Pharmacokinetics, 2014, 53, 849-861.	1.6	32
262	European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clinical Microbiology and Infection, 2014, 20, 19-36.	2.8	53
263	Prospective validation of neonatal vancomycin dosing regimens is urgently needed. Current Therapeutic Research, 2014, 76, 51-57.	0.5	33
264	Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates. Antimicrobial Agents and Chemotherapy, 2014, 58, 6454-6461.	1.4	109
265	Methicillin-resistantStaphylococcus aureuspneumonia in adults. Expert Review of Respiratory Medicine, 2014, 8, 641-651.	1.0	25
266	Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert Review of Anti-Infective Therapy, 2014, 12, 1371-1388.	2.0	12
267	Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. International Journal of Antimicrobial Agents, 2014, 44, 235-241.	1.1	38
268	In Vitro Activity of Human-Simulated Epithelial Lining Fluid Exposures of Ceftaroline, Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2014, 58, 7520-7526.	1.4	17
269	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	2.5	87
270	Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: Where are we now?. Journal of Global Antimicrobial Resistance, 2014, 2, 133-140.	0.9	20
271	Innovative approaches to optimizing the delivery of vancomycin in individual patients. Advanced Drug Delivery Reviews, 2014, 77, 50-57.	6.6	215

#	Article	IF	Citations
272	Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 630-640.	1.3	26
273	Vancomycin Dosing Considerations in a Realâ€World Cohort of Obese and Extremely Obese Patients. Pharmacotherapy, 2015, 35, 869-875.	1.2	22
274	Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients withStaphylococcus aureusBacteremia: A Meta-analysis of Observational Studies. Pharmacotherapy, 2015, 35, 889-898.	1.2	76
275	Vancomycin serum trough concentration vs. clinical outcome in patients with gram-positive infection: a retrospective analysis. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 640-644.	0.7	9
276	Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentrationâ€“Time Curve to the Minimum Inhibitory Concentration â‰¥400 Target. Therapeutic Drug Monitoring, 2015, 37, 756-765.	1.0	21
277	A Case of Ventilator-Associated Pneumoniae Complicated with Antibiotics-induced Severe Drug Eruption. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 651-655.	0.0	0
278	Acute Pneumonia. , 2015, , 823-846.e5.		10
279	Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), Lipopeptides (Daptomycin), and Lipoglycopeptides (Telavancin). , 2015, , 377-400.e4.		13
280	Treatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 017-030.	0.8	50
281	Performance of a Divided-Load Intravenous Vancomycin Dosing Strategy for Obese Patients. Annals of Pharmacotherapy, 2015, 49, 861-868.	0.9	7
282	Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance. Current Infectious Disease Reports, 2015, 17, 493.	1.3	46
283	Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. Journal of the Pediatric Infectious Diseases Society, 2015, 4, e109-e116.	0.6	82
284	Antibiotic dose optimization in critically ill patients. Medicina Intensiva (English Edition), 2015, 39, 563-572.	0.1	2
285	How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. Diagnostic Microbiology and Infectious Disease, 2015, 82, 92-103.	0.8	68
286	Novel pandemic influenza A (H1N1) and community-associated methicillin-resistantStaphylococcus aureuspneumonia. Expert Review of Anti-Infective Therapy, 2015, 13, 197-207.	2.0	21
287	Balancing Vancomycin Efficacy and Nephrotoxicity: Should We Be Aiming for Trough or AUC/MIC?. Paediatric Drugs, 2015, 17, 97-103.	1.3	19
288	Vancomycin Loading Doses. Annals of Pharmacotherapy, 2015, 49, 557-565.	0.9	25
289	Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. Journal of Infection and Chemotherapy, 2015, 21, 319-329.	0.8	169

#	Article	IF	Citations
290	Treatment of community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2015, 13, 1109-1121.	2.0	4
292	Antimicrobial Pharmacokinetics and Pharmacodynamics. Surgical Infections, 2015, 16, 375-379.	0.7	10
293	Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China. Indian Journal of Medical Microbiology, 2015, 33, 262-266.	0.3	28
294	Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. Expert Review of Anti-Infective Therapy, 2015, 13, 1265-1278.	2.0	19
295	Recent Updates on the Role of Pharmacokinetics-pharmacodynamics in Antimicrobial Susceptibility Testing as Applied to Clinical Practice. Clinical Infectious Diseases, 2015, 61, 1446-1452.	2.9	23
296	The authors reply. Critical Care Medicine, 2015, 43, e154-e155.	0.4	1
297	Vancomycin continuous infusion versus intermittent infusion during continuous venovenous hemofiltration: slow and steady may win the race. Annals of Intensive Care, 2015, 5, 10.	2.2	13
298	Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis. Antimicrobial Agents and Chemotherapy, 2015, 59, 2978-2985.	1.4	68
299	Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 136-153.	0.8	134
300	Optimizing Antimicrobial Therapy of Sepsis and Septic Shock: Focus on Antibiotic Combination Therapy. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 154-166.	0.8	49
301	Pediatric Assessment of Vancomycin Empiric Dosing (PAVED): a Retrospective Review. Paediatric Drugs, 2015, 17, 245-253.	1.3	15
302	Antibiotic dose optimization in critically ill patients. Medicina Intensiva, 2015, 39, 563-572.	0.4	39
303	How to use vancomycin optimally in neonates: remaining questions. Expert Review of Clinical Pharmacology, 2015, 8, 635-648.	1.3	28
304	Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients. Journal of Critical Care, 2015, 30, 1153.e1-1153.e6.	1.0	18
305	Impact of area under the concentrationâ€“time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. International Journal of Antimicrobial Agents, 2015, 46, 689-695.	1.1	48
306	High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis. Journal of Chemotherapy, 2015, 27, 213-220.	0.7	13
307	Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring. Journal of Clinical Pharmacology, 2015, 55, 212-220.	1.0	18
308	A retrospective analysis to estimate target trough concentration of vancomycin for febrile neutropenia in patients with hematological malignancy. Clinica Chimica Acta, 2015, 440, 183-187.	0.5	18

#	Article	IF	Citations
309	A Randomized Trial of Loading Vancomycin in the Emergency Department. Annals of Pharmacotherapy, 2015, 49, 6-13.	0.9	40
310	Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range. Infection and Drug Resistance, 2016, 9, 87.	1.1	18
311	Pharmacist-managed dose adjustment feedback using therapeutic drug monitoring of vancomycin was useful for patients with methicillin-resistant Staphylococcus aureus infections: a single institution experience. Infection and Drug Resistance, 2016, Volume 9, 243-252.	1.1	27
312	Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus. Antibiotics, 2016, 5, 34.	1.5	6
313	Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0146224.	1.1	92
314	Unanswered Questions Regarding Optimal Pediatric Vancomycin Use. Therapeutic Drug Monitoring, 2016, 38, 419-420.	1.0	2
315	Vancomycin AUC₂₄/MIC Ratio in Patients with Methicillinâ€Resistant Staphylococcus aureus Pneumonia. Journal of Clinical Laboratory Analysis, 2016, 30, 485-489.	0.9	2
316	Renal Function Descriptors in Neonates: Which Creatinineâ€Based Formula Best Describes Vancomycin Clearance?. Journal of Clinical Pharmacology, 2016, 56, 528-540.	1.0	8
317	Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels. Therapeutic Drug Monitoring, 2016, 38, 120-126.	1.0	17
318	Augmented Renal Clearance in Pediatric Patients With Febrile Neutropenia Associated With Vancomycin Clearance. Therapeutic Drug Monitoring, 2016, 38, 393-397.	1.0	51
319	Healthcare-associated Staphylococcus aureus Bacteremia in Children. Pediatric Infectious Disease Journal, 2016, 35, 263-268.	1.1	43
320	â€œIn Through the Out Doorâ€• Pediatric Critical Care Medicine, 2016, 17, 373-374.	0.2	0
321	Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 399-402.	0.7	18
322	Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?. BMC Pediatrics, 2016, 16, 206.	0.7	31
323	Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw495.	1.3	27
324	Antibiotic Stewardship and Applications of Pharmacodynamics. Methods in Pharmacology and Toxicology, 2016, , 633-647.	0.1	0
325	Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Review of Clinical Pharmacology, 2016, 9, 961-979.	1.3	98
326	New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 4750-4756.	1.4	45

#	Article	IF	Citations
327	Application of Antibiotic Pharmacodynamics and Dosing Principles in Patients With Sepsis. Critical Care Nurse, 2016, 36, 22-32.	0.5	8
328	Empirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach. Journal of Infection and Chemotherapy, 2016, 22, 351-359.	0.8	46
329	In VitroPharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 955-961.	1.4	5
330	Vancomycin Pharmacodynamics: Optimal vs. Controversial. Methods in Pharmacology and Toxicology, 2016, , 261-284.	0.1	0
331	Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application. Drugs and Aging, 2016, 33, 845-854.	1.3	20
332	Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clinical Therapeutics, 2016, 38, 1930-1947.	1.1	112
333	A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 495-502.	1.3	32
334	Augmented Renal Clearance in Patients With Febrile Neutropenia is Associated With Increased Risk for Subtherapeutic Concentrations of Vancomycin. Therapeutic Drug Monitoring, 2016, 38, 706-710.	1.0	64
335	Switching From Intermittent to Continuous Infusion of Vancomycin in Critically Ill Patients. Therapeutic Drug Monitoring, 2016, 38, 398-401.	1.0	16
336	Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrobial Agents and Chemotherapy, 2016, 60, 1013-1021.	1.4	53
337	Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. Journal of Antimicrobial Chemotherapy, 2016, 71, 992-1002.	1.3	37
338	Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 93-114.	1.5	46
339	Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development. , 2016, , 185-217.		7
340	Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. International Journal of Antimicrobial Agents, 2016, 47, 259-268.	1.1	94
341	Optimizing the Clinical Use of Vancomycin. Antimicrobial Agents and Chemotherapy, 2016, 60, 2601-2609.	1.4	182
342	Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates. Antimicrobial Agents and Chemotherapy, 2016, 60, 2039-2042.	1.4	44
343	The use and risks of antibiotics in critically ill patients. Expert Opinion on Drug Safety, 2016, 15, 667-678.	1.0	25
344	SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. BMC Infectious Diseases, 2016, 16, 103.	1.3	14

#	Article	IF	Citations
345	Vancomycin dosing and target attainment in children. Journal of Microbiology, Immunology and Infection, 2017, 50, 494-499.	1.5	26
346	Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC â‰¥ 400 in Patients With Presumed MRSA Infection?. Journal of Pharmacy Practice, 2017, 30, 329-335.	0.5	51
347	Healthcareâ€associated pneumonia with positive respiratory methicillinâ€resistant <scp>S</scp>taphylococcus aureus culture: Predictors of the true pathogenicity. Geriatrics and Gerontology International, 2017, 17, 456-462.	0.7	5
348	A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations. Clinical Pharmacokinetics, 2017, 56, 263-272.	1.6	2
349	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Medicine, 2017, 43, 304-377.	3.9	4,590
350	Assessment of linezolid prescriptions in three French hospitals. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1133-1141.	1.3	7
351	Risk Factors for Non-Therapeutic Initial Steady-State Vancomycin Trough Concentrations in Children and Adolescents Receiving High Empiric Doses of Intravenous Vancomycin. Paediatric Drugs, 2017, 19, 43-51.	1.3	6
352	Cystatin Câ€“Guided Vancomycin Dosing in Critically Ill Patients: AÂQuality Improvement Project. American Journal of Kidney Diseases, 2017, 69, 658-666.	2.1	60
353	Diphenylurea derivatives for combating methicillin- and vancomycin-resistant Staphylococcus aureus. European Journal of Medicinal Chemistry, 2017, 130, 73-85.	2.6	38
354	Establishment of an AUC _{0â€“24} Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	75
355	Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies AgainstStaphylococcus AureusExploitingIn VitroInformation. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 512-522.	1.3	15
356	Vancomycin during the Last Hour of the Hemodialysis Session: A Pharmacokinetic Analysis. Nephron, 2017, 135, 261-267.	0.9	9
357	The Influence of the Route of Antibiotic Administration, Methicillin Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection. Pediatric Infectious Disease Journal, 2017, 36, 572-577.	1.1	53
358	Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1569-1575.	1.3	3
359	Evaluation of the variability and safety of serum trough concentrations of vancomycin in patients admitted to the intensive care unit. International Journal of Infectious Diseases, 2017, 60, 17-22.	1.5	8
360	A simulation of loading doses for vancomycin continuous infusion regimens in intensive care. Infectious Diseases, 2017, 49, 674-679.	1.4	6
361	Comparative Pharmacodynamics of Telavancin and Vancomycin in the Neutropenic Murine Thigh and Lung Infection Models against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	22
362	Epidemiology of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children. Pediatrics, 2017, 139, .	1.0	42

#	Article	IF	Citations
363	Optimal teicoplanin dosage regimens for methicillin-resistantStaphylococcus aureusinfections in endocarditis patients and renal failure patients. Journal of Chemotherapy, 2017, 29, 358-364.	0.7	3
364	The Whole Price of Vancomycin: Toxicities, Troughs, and Time. Drugs, 2017, 77, 1143-1154.	4.9	121
365	Pharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	25
366	Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases, 2017, 64, S24-S29.	2.9	48
367	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Critical Care Medicine, 2017, 45, 486-552.	0.4	2,336
368	Antibiotic dosing for multidrug-resistant pathogen pneumonia. Current Opinion in Infectious Diseases, 2017, 30, 231-239.	1.3	13
369	AUC/MIC Pharmacodynamic Target Is Not a Good Predictor of Vancomycin Efficacy in Methicillin-Resistant Staphylococcus aureus Experimental Endocarditis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	7
370	Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). Expert Review of Clinical Pharmacology, 2017, 10, 493-508.	1.3	2
372	Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Clinical Study in Elderly Patients. Therapeutic Drug Monitoring, 2017, 39, 83-87.	1.0	40
373	Impact of Higher Vancomycin Troughs on Vancomycin-Induced Nephrotoxicity. Infectious Diseases in Clinical Practice, 2017, 25, 203-208.	0.1	1
374	Arylthiazole antibiotics targeting intracellular methicillin-resistant Staphylococcus aureus (MRSA) that interfere with bacterial cell wall synthesis. European Journal of Medicinal Chemistry, 2017, 139, 665-673.	2.6	46
375	DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates. Therapeutic Drug Monitoring, 2017, 39, 604-613.	1.0	15
376	Clinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis. BMC Nephrology, 2017, 18, 168.	0.8	15
377	Optimization of anti-infective dosing regimens during online haemodiafiltration. CKJ: Clinical Kidney Journal, 2017, 10, 282-290.	1.4	10
378	Comment on: Trimethoprim/sulfamethoxazole versus vancomycin in the treatment of healthcare/ventilator-associated MRSA pneumonia: a caseâ€“control study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2684-2685.	1.3	2
379	Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance. European Journal of Hospital Pharmacy, 2019, 26, ejhpharm-2017-001396.	0.5	12
380	Optimisation of Antimicrobial Dosing Based on Pharmacokinetic and Pharmacodynamic Principles. Indian Journal of Medical Microbiology, 2017, 35, 340-346.	0.3	9
381	Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-ResistantStaphylococcus aureusBacteremia in Children. Journal of Korean Medical Science, 2017, 32, 22.	1.1	22

#	Article	IF	Citations
382	Impact of a pharmacist-driven methicillin-resistantStaphylococcus aureussurveillance protocol. American Journal of Health-System Pharmacy, 2017, 74, 1765-1773.	0.5	29
383	Therapeutic Drug Monitoring of Beta-Lactams and Other Antibiotics in the Intensive Care Unit: Which Agents, Which Patients and Which Infections?. Drugs, 2018, 78, 439-451.	4.9	95
384	Alkynyl-containing phenylthiazoles: Systemically active antibacterial agents effective against methicillin-resistant Staphylococcus aureus (MRSA). European Journal of Medicinal Chemistry, 2018, 148, 195-209.	2.6	36
385	Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides. Clinical Pharmacokinetics, 2018, 57, 797-816.	1.6	17
386	The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review. Paediatric Drugs, 2018, 20, 153-164.	1.3	41
387	Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	28
388	Nephrotoxicity With Vancomycin in the Pediatric Population. Pediatric Infectious Disease Journal, 2018, 37, 654-661.	1.1	48
389	Vancomycin dosing in chronic high-flux haemodialysis: a systematic review. International Journal of Antimicrobial Agents, 2018, 51, 678-686.	1.1	8
390	Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 259-268.	0.6	33
391	Continuous intravenous vancomycin in children with normal renal function hospitalized in hematologyâ€“oncology: prospective validation of a dosing regimen optimizing steadyâ€state concentration. Fundamental and Clinical Pharmacology, 2018, 32, 323-329.	1.0	8
392	Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
393	Vancomycin and daptomycin minimum inhibitory concentrations as a predictor of outcome of methicillin-resistant Staphylococcus aureus bacteraemia. Journal of Global Antimicrobial Resistance, 2018, 14, 141-144.	0.9	8
395	Pharmacokinetics of Antimicrobials in Endophthalmitis. , 2018, , 265-280.		0
396	Antibiotic Dosing in Pediatric Critically Ill Patients. , 2018, , 239-263.		3
397	The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: An appraisal utilizing antibiotics. Advanced Drug Delivery Reviews, 2018, 123, 65-74.	6.6	46
398	Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill. , 2018, , .		3
399	Augmented Renal Clearance. , 2018, , 125-150.		3
400	Importance of vancomycin loading doses in intermittent infusion regimens. Journal of Infection and Chemotherapy, 2018, 24, 247-250.	0.8	15

#	Article	IF	Citations
401	Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	263
402	Characterization of variables for potential impact on vancomycin pharmacokinetics in thermal or inhalation injury. Burns, 2018, 44, 658-664.	1.1	8
403	Considerations regarding PK/PD theory for antibiotics treatment from a pharmacokinetic perspective. Drug Delivery System, 2018, 33, 10-17.	0.0	1
404	A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring. Clinical Infectious Diseases, 2018, 67, S249-S255.	2.9	35
405	Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients. Clinical Infectious Diseases, 2018, 67, S256-S262.	2.9	18
406	Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial. BMJ Open, 2018, 8, e022603.	0.8	5
407	Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. Journal of Thoracic Disease, 2018, 10, S629-S641.	0.6	110
408	Naphthylthiazoles: Targeting Multidrug-Resistant and Intracellular Staphylococcus aureus with Biofilm Disruption Activity. ACS Infectious Diseases, 2018, 4, 1679-1691.	1.8	26
409	Review and Validation of Bayesian Doseâ€Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients. Pharmacotherapy, 2018, 38, 1174-1183.	1.2	93
410	Making the change to area under the curveâ€“based vancomycin dosing. American Journal of Health-System Pharmacy, 2018, 75, 1986-1995.	0.5	68
411	Effects of pharmacist intervention in Vancomycin treatment for patients with bacteremia due to Methicillin-resistant Staphylococcus aureus. PLoS ONE, 2018, 13, e0203453.	1.1	16
412	Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation. SAGE Open Medicine, 2018, 6, 205031211877325.	0.7	16
413	What Every Steward Should Know About Pharmacokinetics and Pharmacodynamics. , 0, , 155-174.		0
414	Staphylococcus aureus. Pediatrics in Review, 2018, 39, 287-298.	0.2	32
415	Population Pharmacokinetics of Vancomycin in Patients Undergoing Allogeneic Hematopoietic Stemâ€Cell Transplantation. Journal of Clinical Pharmacology, 2018, 58, 1140-1149.	1.0	18
416	Appropriateness of vancomycin therapeutic drug monitoring and its outcomes among non-dialysis patients in a tertiary hospitalÂin Singapore. International Journal of Clinical Pharmacy, 2018, 40, 977-981.	1.0	11
417	Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population. Diagnostic Microbiology and Infectious Disease, 2018, 92, 346-351.	0.8	22
418	Management of Pediatric Acute Hematogenous Osteomyelitis, Part <scp>II</scp>: A Focus on Methicillinâ€Resistant Staphylococcus aureus, Current and Emerging Therapies. Pharmacotherapy, 2018, 38, 1021-1037.	1.2	12

#	Article	IF	Citations
419	The Importance of Individualized Vancomycin Dosing to Ensure Optimal Exposure Early in Therapy. Journal of Clinical Pharmacology, 2018, 58, 1131-1133.	1.0	4
420	The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia. PLoS ONE, 2018, 13, e0193585.	1.1	18
421	Neonates are not just little children and need more finesse in dosing of antibiotics. Acta Clinica Belgica, 2019, 74, 157-163.	0.5	12
422	Vancomycin is commonly underâ€dosed in critically ill children and neonates. British Journal of Clinical Pharmacology, 2019, 85, 2591-2598.	1.1	28
423	Describing vancomycin serum levels in pediatric intensive care unit (ICU) patients: are expected goals being met. BMC Pediatrics, 2019, 19, 240.	0.7	8
424	Optimizing Vancomycin Use Through 2â€Point AUCâ€Based Therapeutic Drug Monitoring in Pediatric Patients. Journal of Clinical Pharmacology, 2019, 59, 1597-1605.	1.0	19
425	Appropriateness of basing vancomycin dosing on area under the concentrationâ€“time curve. American Journal of Health-System Pharmacy, 2019, 76, 1718-1721.	0.5	3
426	Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes. International Journal of Antimicrobial Agents, 2019, 54, 702-708.	1.1	16
427	Early Bayesian Dose Adjustment of Vancomycin Continuous Infusion in Children in a Randomized Controlled Trial. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	14
428	Actual body weight-based vancomycin dosing in neonates. Journal of Chemotherapy, 2019, 31, 307-312.	0.7	8
429	The importance of dosing interval in limiting vancomycin AUC with trough monitoring. American Journal of Health-System Pharmacy, 2020, 77, 487-492.	0.5	5
430	Development and external evaluation of a population pharmacokinetic model for continuous and intermittent administration of vancomycin in neonates and infants using prospectively collected data. Journal of Antimicrobial Chemotherapy, 2019, 74, 1003-1011.	1.3	20
431	Vancomycin-Associated Acute Kidney Injury in a Large Veteran Population. American Journal of Nephrology, 2019, 49, 133-142.	1.4	20
432	Vancomycin pharmacokinetics in critically ill obese patients: can the clinician sit back and relax?. Critical Care, 2019, 23, 15.	2.5	3
433	Defining Target Vancomycin Trough Concentrations for Treating Staphylococcus aureus Infection in Infants Aged 0 to 90 Days. JAMA Pediatrics, 2019, 173, 791.	3.3	5
435	Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert Review of Clinical Pharmacology, 2019, 12, 623-634.	1.3	36
436	Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	9
437	Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease. Wiener Klinische Wochenschrift, 2019, , 1.	1.0	1

#	Article	IF	Citations
438	Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin. Scientific Reports, 2019, 9, 3247.	1.6	32
439	Clinical and Pharmacokinetic Outcomes of Peakâ€“Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 639-652.	0.6	21
440	Revising Pediatric Vancomycin Dosing Accounting for Nephrotoxicity in a Pharmacokinetic-Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
441	Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates. British Journal of Clinical Pharmacology, 2019, 85, 865-867.	1.1	15
442	Nomogram based on actual body weight for estimation of vancomycin maintenance dose in infants. Infectious Diseases, 2019, 51, 334-339.	1.4	3
443	An Inhibitory Effect of Dryocrassin ABBA on Staphylococcus aureus vWbp That Protects Mice From Pneumonia. Frontiers in Microbiology, 2019, 10, 7.	1.5	11
444	Monocytes Represent One Source of Bacterial Shielding from Antibiotics following Influenza Virus Infection. Journal of Immunology, 2019, 202, 2027-2034.	0.4	10
445	AUC-Based Monitoring of Vancomycin: Closing the Therapeutic Window. journal of applied laboratory medicine, The, 2019, 3, 743-746.	0.6	8
446	Assessment of Empiric Vancomycin Regimen in the Neonatal Intensive Care Unit. Canadian Journal of Hospital Pharmacy, 2019, 72, .	0.1	2
447	Initial dosing of intermittent vancomycin in adults: estimation of dosing interval in relation to dose and renal function. European Journal of Hospital Pharmacy, 2019, 28, ejhpharm-2019-002013.	0.5	5
449	The clinical efficacy and safety of vancomycin loading dose. Medicine (United States), 2019, 98, e17639.	0.4	18
450	Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 103-112.	1.5	18
451	The dosing and monitoring of vancomycin: what is the best way forward?. International Journal of Antimicrobial Agents, 2019, 53, 401-407.	1.1	47
452	Vancomycin dosing, monitoring and toxicity: Critical review of the clinical practice. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 292-301.	0.9	33
453	An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillinâ€Resistant Staphylococcus aureus. Journal of Clinical Pharmacology, 2019, 59, 198-205.	1.0	15
454	Optimization of an empiric vancomycin dosing algorithm for improved target concentration attainment in patients with thermal injury. Burns, 2019, 45, 423-432.	1.1	7
456	The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant Staphylococcus aureus Infection. Journal of Pharmacy Practice, 2019, 32, 442-446.	0.5	18
457	Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 97-104.	0.6	34

#	Article	IF	Citations
458	Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacological Research, 2020, 154, 104278.	3.1	25
459	The Emperorâ€™s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clinical Infectious Diseases, 2020, 70, 1536-1545.	2.9	106
460	Vancomycin Area Under the Curve Dosing and Monitoring at an Academic Medical Center: Transition Strategies and Lessons Learned. Journal of Pharmacy Practice, 2020, 33, 774-778.	0.5	19
461	Vancomycin drug monitoring in infants with CoNS sepsis-target attainment, microbiological response and nephrotoxicity. Journal of Perinatology, 2020, 40, 97-104.	0.9	7
462	Utilization of Augmented Renal Clearance in Trauma Intensive Care Scoring System to Improve Vancomycin Dosing in Trauma Patients at Risk for Augmented Renal Clearance. Surgical Infections, 2020, 21, 43-47.	0.7	8
463	Modifying the lipophilic part of phenylthiazole antibiotics to control their drug-likeness. European Journal of Medicinal Chemistry, 2020, 185, 111830.	2.6	20
464	Vancomycin therapeutic drug monitoring in paediatrics. Journal of Paediatrics and Child Health, 2020, 56, 563-570.	0.4	9
465	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. British Journal of Clinical Pharmacology, 2020, 86, 303-317.	1.1	37
466	Retrospective multicentre matched cohort study comparing safety and efficacy outcomes of intermittent-infusion versus continuous-infusion vancomycin. Journal of Antimicrobial Chemotherapy, 2020, 75, 1038-1046.	1.3	8
467	Using AUC/MIC to guide vancomycin dosing: ready for prime time?. Clinical Microbiology and Infection, 2020, 26, 406-408.	2.8	11
468	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 791-797.	1.3	51
469	Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity. Clinical Microbiology and Infection, 2020, 26, 436-446.	2.8	41
470	Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Targetâ€“Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia. Annals of Pharmacotherapy, 2020, 54, 644-651.	0.9	15
471	Is Early Monitoring Better? Impact of Early Vancomycin Exposure on Treatment Outcomes and Nephrotoxicity in Patients with Methicillin-Resistant Staphylococcus aureus Infections. Antibiotics, 2020, 9, 672.	1.5	11
472	What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?. Pharmaceutics, 2020, 12, 638.	2.0	33
473	Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. Antibiotics, 2020, 9, 793.	1.5	6
474	A higher dose of vancomycin is needed in critically ill patients with augmented renal clearance. Translational Andrology and Urology, 2020, 9, 2166-2171.	0.6	13
475	Comparison of intermittent versus continuous-infusion vancomycin for treating severe patients in intensive care units. Brazilian Journal of Infectious Diseases, 2020, 24, 356-359.	0.3	8

#	Article	IF	Citations
476	A Moving Targetâ€"Vancomycin Therapeutic Monitoring. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 474-478.	0.6	16
477	Optimization of Vancomycin Dosing Regimen in Cancer Patients using Pharmacokinetic/Pharmacodynamic Modeling. Pharmacotherapy, 2020, 40, 1192-1200.	1.2	10
478	Evaluation of vancomycin initial trough levels in children: A 1-year retrospective study. SAGE Open Medicine, 2020, 8, 205031212095105.	0.7	3
479	Development of Biphenylthiazoles Exhibiting Improved Pharmacokinetics and Potent Activity Against Intracellular Staphylococcus aureus. ACS Infectious Diseases, 2020, 6, 2887-2900.	1.8	11
480	Prospective validation of a modelâ€informed precision dosing tool for vancomycin in intensive care patients. British Journal of Clinical Pharmacology, 2020, 86, 2497-2506.	1.1	25
481	Aerosol-to-Hydrosol Sampling and Simultaneous Enrichment of Airborne Bacteria For Rapid Biosensing. ACS Sensors, 2020, 5, 2763-2771.	4.0	20
482	Influence of venovenous extracorporeal membrane oxygenation on pharmacokinetics of vancomycin in lung transplant recipients. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1066-1075.	0.7	7
483	Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 1278-1287.	0.7	18
484	Therapeutic monitoring of vancomycin for serious methicillin-resistantStaphylococcus aureusinfections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. American Journal of Health-System Pharmacy, 2020, 77, 835-864.	0.5	640
485	Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 415-430.	1.5	14
486	Factors increasing the risk of inappropriate vancomycin therapy in ICU patients: A prospective observational study. Acta Anaesthesiologica Scandinavica, 2020, 64, 1295-1304.	0.7	8
487	Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection?. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	2
488	Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy. Peritoneal Dialysis International, 2020, 40, 384-393.	1.1	15
489	The antibiotic vancomycin induces complexation and aggregation of gastrointestinal and submaxillary mucins. Scientific Reports, 2020, 10, 960.	1.6	23
490	AUC- vs. Trough-Guided Monitoring of Vancomycin in Infants. Indian Journal of Pediatrics, 2020, 87, 359-364.	0.3	13
491	Treating Intracranial Abscesses in Rats with Stereotactic Injection of Biodegradable Vancomycin-Embedded Microparticles. Pharmaceutics, 2020, 12, 91.	2.0	6
492	Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration. BMC Infectious Diseases, 2020, 20, 74.	1.3	3
493	Correlation of the vancomycin 24-h area under the concentration-time curve (AUC24) and trough serum concentration in children with severe infection: A clinical pharmacokinetic study. International Journal of Infectious Diseases, 2020, 92, 151-159.	1.5	27

#	Article	IF	Citations
495	Pharmacokinetic and Pharmacodynamic Characteristics of Vancomycin and Meropenem in Critically Ill Patients Receiving Sustained Low-efficiency Dialysis. Clinical Therapeutics, 2020, 42, 625-633.	1.1	15
496	The risk of vancomycin toxicity in patients with liver impairment. Annals of Clinical Microbiology and Antimicrobials, 2020, 19, 13.	1.7	8
497	Weight-based vancomycin loading strategy may not improve achievement of optimal vancomycin concentration in patients with preserved renal function. Journal of Chemotherapy, 2021, 33, 56-61.	0.7	3
498	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical Infectious Diseases, 2021, 72, 1369-1378.	2.9	85
499	Personalised dosing of vancomycin: A prospective and retrospective comparative quasiâ€experimental study. British Journal of Clinical Pharmacology, 2021, 87, 506-515.	1.1	14
500	Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115292.	0.8	15
501	Evaluation of a trough-only extrapolated area under the curve vancomycin dosing method on clinical outcomes. International Journal of Clinical Pharmacy, 2021, 43, 263-269.	1.0	6
502	Heaping the Pelion of Vancomycin on the Ossa of Methicillin-resistant Staphylococcus aureus: Back to Basics in Clinical Care and Guidelines. Clinical Infectious Diseases, 2021, 72, e682-e684.	2.9	10
503	Pharmacist Survey: Pharmacist Perception of Vancomycin Area Under the Curve Therapeutic Drug Monitoring. Journal of Pharmacy Practice, 2021, 34, 272-278.	0.5	9
504	Therapeutic drug monitoring. , 2021, , 243-262.		4
505	Association Between Vancomycin Area Under the Curve and Nephrotoxicity: a single center, retrospective cohort study in a veteran population. Open Forum Infectious Diseases, 2021, 8, ofab094.	0.4	14
506	Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review. Antibiotics, 2021, 10, 347.	1.5	6
507	AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. Journal of Antimicrobial Chemotherapy, 2021, 76, 2237-2251.	1.3	15
508	Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?. Journal of Clinical Microbiology, 2021, 59, .	1.8	1
509	Should Therapeutic Drug Monitoring Based on the Vancomycin Area Under the Concentration-Time Curve Be Standard for Serious Methicillin-Resistant Staphylococcus aureus Infections?â€”No. Clinical Infectious Diseases, 2021, 72, 1502-1506.	2.9	14
510	Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. Journal of Global Antimicrobial Resistance, 2021, 24, 403-410.	0.9	7
511	Contribution of Population Pharmacokinetics of Glycopeptides and Antifungals to Dosage Adaptation in Paediatric Onco-hematological Malignancies: A Review. Frontiers in Pharmacology, 2021, 12, 635345.	1.6	1
512	Competence Mining of Vancomycin (VAN) in the Management of Infections Due to Bacterial Strains With High VAN Minimum Inhibitory Concentrations (MICs): A Novel Dosing Strategy Based on Pharmacokinetic/Pharmacodynamic Modeling. Frontiers in Microbiology, 2021, 12, 649757.	1.5	5

#	Article	IF	Citations
513	Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children. PLoS ONE, 2021, 16, e0247714.	1.1	6
514	Pediatric Antibiotic Stewardship. Pediatric Infectious Disease Journal, 2021, 40, 556-562.	1.1	6
515	Optimizing Antimicrobial Drug Dosing in Critically Ill Patients. Microorganisms, 2021, 9, 1401.	1.6	27
517	Relationship Between Mean Vancomycin Trough Concentration and Mortality in Critically Ill Patients: A Multicenter Retrospective Study. Frontiers in Pharmacology, 2021, 12, 690157.	1.6	2
518	Optimal Sampling Strategy and Threshold of Serum Vancomycin Concentration in Elderly Japanese Patients undergoing High-flux Hemodialysis. Therapeutic Drug Monitoring, 2021, Publish Ahead of Print, .	1.0	0
519	A Monocentric Retrospective Study of AUC/MIC Ratio of Vancomycin Associated with Clinical Outcomes and Nephrotoxicity in Patients with Enterococcal Infections. Pharmaceutics, 2021, 13, 1378.	2.0	18
520	Bactericidal and Bacteriostatic Antibiotics. , 0, , .		2
521	Continuous infusion versus intermittent infusion vancomycin in a burn center intensive care unit. Burns, 2021, 47, 1495-1501.	1.1	7
522	Hospital Pharmacometrics for Optimal Individual Administration of Antimicrobial Agents for Anti-methicillin-resistant Staphylococcus aureus Infected Patients. Biological and Pharmaceutical Bulletin, 2021, 44, 1174-1183.	0.6	1
523	Optimizing outcomes using vancomycin therapeutic drug monitoring in patients with MRSA bacteremia: trough concentrations or area under the curve?. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115442.	0.8	4
524	Continuous infusion of vancomycin improved therapeutic levels in term and preterm infants. Journal of Perinatology, 2021, 41, 1459-1466.	0.9	2
525	Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions. Clinical Pharmacokinetics, 2021, 60, 409-445.	1.6	12
526	Pharmacometrics in Bacterial Infections. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 229-258.	0.2	13
527	Antibiotic Dosing During Extracorporeal Membrane Oxygenation. , 2018, , 151-171.		2
528	Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), and Lipopeptides (Daptomycin). , 2010, , 449-467.		6
529	Cost comparison of AUC:MICâ€“ versus trough-based vancomycin monitoring for MRSA bacteremia. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 729-733.	0.7	3
530	Comparison of open-access vancomycin dosing websites. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 128-131.	0.7	6
531	Quantification of vancomycin in human serum by LC-MS/MS. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1761-9.	1.4	33

#	Article	IF	Citations
532	Antibiotic prescription in intensive care units in Latin America. Revista Argentina De Microbiologia, 2011, 43, 203-11.	0.4	25
533	Vancomycin-releasing cross-linked collagen sponges as wound dressings. Bosnian Journal of Basic Medical Sciences, 2021, 21, 61-70.	0.6	7
534	Staphylococcus aureus: Resistance Update and Treatment Options. Infectious Disease and Therapy, 2007, , 75-88.	0.0	1
535	Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines. Annals of Laboratory Medicine, 2014, 34, 1-6.	1.2	4
536	Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients. Korean Journal of Pediatrics, 2010, 53, 1000.	1.9	17
537	Therapeutic monitoring of vancomycin in clinical practice. Klinicka Farmakologie A Farmacie, 2016, 30, 4-8.	0.1	3
538	Multidrug-Resistant Gram-Positive Bacterial Infections. Korean Journal of Medicine, 2015, 88, 487.	0.1	3
539	Optimizing Antibiotic Pharmacodynamics for Clinical Practice. Pharmaceutica Analytica Acta, 2013, 04, .	0.2	18
540	Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction. World Journal of Nephrology, 2015, 4, 330.	0.8	10
541	Vancomycin Dosing and Pharmacokinetics in Postoperative Pediatric Cardiothoracic Surgery Patients. Journal of Pediatric Pharmacology and Therapeutics, 2016, 21, 66-74.	0.3	9
542	Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population. Journal of Pediatric Pharmacology and Therapeutics, 2017, 22, 41-47.	0.3	50
543	Predictors of Adverse Outcomes in Children With Staphylococcus aureus Bacteremia. Journal of Pediatric Pharmacology and Therapeutics, 2017, 22, 218-226.	0.3	9
544	Therapeutic Drug Monitoring of Vancomycin in Adult Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia or Pneumonia. Canadian Journal of Hospital Pharmacy, 2021, 74, 334-343.	0.1	1
545	Analysis of Risk Factors Associated with Reduced Trough Concentrations of Vancomycin in Relation to Renal Function in a Tertiary Hospital in Japan. Infection and Drug Resistance, 2021, Volume 14, 4207-4214.	1.1	0
546	Impact of silicone oil tamponade on intravitreally injected vancomycin pharmacokinetics in cynomolgus monkey eyes. International Journal of Pharmaceutics, 2021, 609, 121185.	2.6	1
547	Effectiveness of Monitoring Use of Agents for Methicillin-resistant Staphylococcus aureus Infection in Ensuring Proper Use. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2008, 34, 1120-1126.	0.0	1
548	MRSAæ„Ÿæ Ÿ“ç—‡æ²»ç™‚ã®è‡¨åºŠåŠ¹æžœã«å½±éŸ¿ã‚’åŠã¼ã™å›ºæ„„éŠæ‘‚å•–æ—¹æ³•ã«é—¢ã™ã‚‹æ–‡çŒ®çš„è€ƒå¯Ÿ.	Japanese Journal of Environ	
549	Fluctuation in PK/PD Parameters and Adverse Reactions of Vancomycin. Iryo Yakugaku (Japanese) Tj ETQq1 1 0.784314 rgBT /Overloc	0.0	0

#	Article	IF	Citations
550	Evaluation of Japanese GFR Estimation Equation for Setting Initial Dose of Vancomycin-Comparison with Cockcroft & Gault equation-. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.2	2
551	Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance. Yearbook of Intensive Care and Emergency Medicine, 2010, , 495-506.	0.1	0
552	Antibiotic Stewardship: Possibilities when Resources Are Limited. , 2010, , 257-269.		0
553	Antibiotic Stewardship: Possibilities when Resources Are Limited. Yearbook of Intensive Care and Emergency Medicine, 2010, , 257-269.	0.1	1
554	Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance. , 2010, , 495-506.		3
555	Anti-Infectives. , 2011, , 153-204.		0
556	2. Review and Prospect of Vancomycin. Japanese Journal of Clinical Pharmacology and Therapeutics, 2012, 43, 215-221.	0.1	0
557	Optimizing Vancomycin Dosing in Obese and Morbidly Obese Patients with MRSA Infections. Advances in Pharmacoepidemiology & Drug Safety, 2012, 01, .	0.1	1
558	Pharmacokinetics-guided vancomycin therapy in pediatric intensive care patients is like trying archery with rodeo. Journal of the Japanese Society of Intensive Care Medicine, 2013, 20, 561-563.	0.0	0
559	Antibiotics in Treatment of Periprosthetic Joint Infections. , 2014, , 107-123.		0
560	Development and Implementation System of the Initial Dose Setting for Vancomycin in the Night Shift. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2014, 40, 85-93.	0.0	1
561	Effort to Increase The Proportion of Patients Undergoing Therapeutic Drug Monitoring and Clinical Evaluation Among Patients Receiving Vancomycin Therapy in Our Hospital. Japanese Journal of Environmental Infections, 2014, 29, 117-121.	0.1	0
562	and Pediatric Kidney Injury. , 2014, , 1-42.		0
563	Treatment of methicillin-resistantStaphylococcus aureusinfections: Importance of high vancomycin minumum inhibitory concentrations. World Journal of Clinical Infectious Diseases, 2015, 5, 14.	0.5	1
564	Nephrotoxins and Pediatric Kidney Injury. , 2016, , 1655-1691.		1
565	Glycopeptides and Antibiotics for Gram-positive Bacterial Infections. , 2016, , 63-76.		0
566	Antibiotic Pharmacodynamics. , 2018, , 17-29.		2
567	The use of Monte Carlo simulation to predict vancomycin dosage for methicillin-resistant Staphylococcus aureus in Thai patients of various ages and with varying degrees of renal function. Asian Biomedicine, 2018, 11, 379-386.	0.2	1

#	Article	IF	Citations
568	Pharmacodynamic Evaluation: Infectious Diseases. , 2018, , 1-18.		0
569	Parameters of vancomycin pharmacokinetics in postoperative patients with renal dysfunction: comparing the results of a pharmacokinetic study and mathematical modeling. Bulletin of Russian State Medical University, 2018, , 58-64.	0.3	0
570	Single-dose and Steady-state Pharmacokinetics of Vancomycin in Critically Ill Patients Admitted to Medical Intensive Care Unit of India. Indian Journal of Critical Care Medicine, 2019, 23, 513-517.	0.3	2
571	Vancomycin Treatment Failure in Children With Methicillin-Resistant Staphylococcus aureus Bacteremia. Journal of Pediatric Pharmacology and Therapeutics, 2019, 24, 312-319.	0.3	5
573	The characteristics and impact indicator of vancomycin pharmacokinetics in cancer patients complicated with severe pneumonia. Journal of Infection and Chemotherapy, 2020, 26, 492-497.	0.8	7
574	Effect of Vancomycin Loading Doses on the Attainment of Target Trough Concentrations in Hospitalized Children. Journal of Pediatric Pharmacology and Therapeutics, 2020, 25, 423-430.	0.3	4
575	Continuous Versus Intermittent Infusion of Vancomycin: Toward the End of the Controversy or Even Closer to the Swan Song?*. Critical Care Medicine, 2020, 48, 932-933.	0.4	1
576	A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100970.	0.6	21
577	Pharmacodynamic Evaluation: Infectious Diseases. , 2020, , 325-342.		0
578	Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range. Therapeutic Drug Monitoring, 2022, 44, 19-31.	1.0	31
579	Study on Initial Dose of Vancomycin Hydrochloride Using Estimated Pharmacokinetic Parameters in Pediatric Patients. Japanese Journal of Environmental Infections, 2020, 35, 151-156.	0.1	0
580	Therapeutic drug monitoring. Klinicka Farmakologie A Farmacie, 2020, 34, 47-55.	0.1	1
581	Antibiotics for pulmonary infections: an overview. , 0, , 1-20.		0
582	Antibiotics in critical care: dosing, therapeutic drug monitoring and continuous infusions. , 0, , 44-56.		0
583	Association of Initial Trough Concentrations of Vancomycin with Outcomes in Pediatric Patients with Gram-Positive Bacterial Infection. Biological and Pharmaceutical Bulletin, 2020, 43, 1463-1468.	0.6	1
584	Evaluation of the Association between Trough and Area Under the Curve to Minimum Inhibitory Concentration Ratio (AUC24/MIC) of Vancomycin in Infected Patients with Methicillin Resistant Staphylococcus aureus (MRSA). Pharmaceutical Sciences, 2020, 27, 201-208.	0.1	2
585	Assessment of Empiric Vancomycin Regimen in the Neonatal Intensive Care Unit. Canadian Journal of Hospital Pharmacy, 2019, 72, 211-218.	0.1	2
586	How Much Vancomycin Dose Is Enough For The MRSA Infection in Pediatric Patients With Various Degrees of Renal Function?. Iranian Journal of Pharmaceutical Research, 2019, 18, 995-1009.	0.3	1

#	Article	IF	Citations
587	Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Infection?. Canadian Journal of Hospital Pharmacy, 2020, 73, 232-237.	0.1	3
588	Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis. Antibiotics, 2021, 10, 1392.	1.5	7
589	Appropriate Use of Glycopeptide Antibiotics and Therapeutic Drug Monitoring for Invasive Infections. Korean Journal of Medicine, 2021, 96, 463-477.	0.1	0
591	Vancomycin therapeutic monitoring by measured trough concentration versus Bayesianâ€derived area under the curve in critically ill patients with cancer. Pharmacology Research and Perspectives, 2022, 10, e00912.	1.1	3
592	The Thirty-Day Mortality Rate and Nephrotoxicity Associated With Trough Serum Vancomycin Concentrations During Treatment of Enterococcal Infections: A Propensity Score Matching Analysis. Frontiers in Pharmacology, 2021, 12, 773994.	1.6	9
593	Comparison of Bayesianâ€derived and firstâ€order analytic equations for calculation of vancomycin area under the curve. Pharmacotherapy, 2022, 42, 284-291.	1.2	10
594	A Systematic Review on Clinical Safety and Efficacy of Vancomycin Loading Dose in Critically Ill Patients. Antibiotics, 2022, 11, 409.	1.5	6
595	Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. Expert Review of Anti-Infective Therapy, 2022, 20, 963-979.	2.0	5
596	Pharmacokinetics and pharmacodynamics of peptide antibiotics. Advanced Drug Delivery Reviews, 2022, 183, 114171.	6.6	13
597	Optimized sampling to estimate vancomycin drug exposure: Comparison of pharmacometric and equationâ€based approaches in a simulationâ€estimation study. CPT: Pharmacometrics and Systems Pharmacology, 2022, , .	1.3	8
602	Implementation of a Vancomycin Dose-Optimization Protocol in Neonates: Impact on Vancomycin Exposure, Biological Parameters, and Clinical Outcomes. Antimicrobial Agents and Chemotherapy, 2022, , e0219121.	1.4	2
604	Continuous vancomycin infusion versus intermittent infusion in critically ill patients: The research protocol. Clinical Critical Care, 2022, , .	0.0	0
606	Association between Augmented Renal Clearance and Inadequate Vancomycin Pharmacokinetic/Pharmacodynamic Targets in Chinese Adult Patients: A Prospective Observational Study. Antibiotics, 2022, 11, 837.	1.5	5
607	Predicted Vancomycin Dosage Requirement in Patients With Hematological Malignancies and Dosage Dynamic Adjustment. Frontiers in Pharmacology, 0, 13, .	1.6	2
608	Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 419-427.	0.3	0
609	Î²-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value. , 2022, 4, e0726.		14
610	External Validation of a Vancomycin Population Pharmacokinetic Model and Developing a New Dosage Regimen in Neonates. European Journal of Drug Metabolism and Pharmacokinetics, 0, , .	0.6	0
611	Norvancomycin for the treatment of central nervous system MRSA infections: A randomized controlled trial. European Journal of Pharmaceutical Sciences, 2022, 177, 106266.	1.9	2

#	Article	IF	Citations
612	A study to explore the appropriateness of dosing regimen of vancomycin in critically ill patients in a tertiary care unit of India. Germs, 2022, 12, 238-252.	0.5	2
613	Machines that help machines to help patients: optimising antimicrobial dosing in patients receiving extracorporeal membrane oxygenation and renal replacement therapy using dosing software. Intensive Care Medicine, 2022, 48, 1338-1351.	3.9	15
614	Vancomycin dosing in patients with obesity. American Journal of Health-System Pharmacy, 0, , .	0.5	0
615	Use of Antibiotics in Preterm Newborns. Antibiotics, 2022, 11, 1142.	1.5	4
616	Sequence Type 5 (ST5) as a Possible Predictor of Bacterial Persistence in Adult Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia Treated with Vancomycin. Microbiology Spectrum, 2022, 10, .	1.2	2
617	Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study. Antibiotics, 2022, 11, 1239.	1.5	4
618	A Systematic Review of the Effect of Therapeutic Drug Monitoring on Patient Health Outcomes during Treatment with Carbapenems. Antibiotics, 2022, 11, 1311.	1.5	4
619	Optimization of Pediatric Antibiotic Dosing Through Therapeutic Drug Monitoring. Current Treatment Options in Pediatrics, 0, , .	0.2	0
620	Association between Vancomycin Pharmacokinetic Parameters and Clinical and Microbiological Efficacy in a Cohort of Neonatal Patients. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	1
622	Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in pediatric patients with Staphylococcus aureus bacteremia. Minerva Pediatrics, 2022, 74, .	0.2	2
623	Comparison of Open-Access, Trough-Only Online Calculators Versus Trapezoidal Method for Calculation of Vancomycin Area Under the Curve (AUC). Annals of Pharmacotherapy, 0, , 106002802211388.	0.9	2
624	When and How to Use MIC in Clinical Practice?. Antibiotics, 2022, 11, 1748.	1.5	5
625	Comparison of the mathematical equation and trapezoidal approach for 24â€‰h area under the plasma concentrationâ€time curve calculation in patients who received intravenous vancomycin in an acute care setting. Pharmacology Research and Perspectives, 2023, 11, .	1.1	0
626	Continuous Vancomycin Infusion versus Intermittent Infusion in Critically Ill Patients. Infection and Drug Resistance, 0, Volume 15, 7751-7760.	1.1	2
627	Area-Under-Curveâ€“Guided Versus Trough-Guided Monitoring of Vancomycin and Its Impact on Nephrotoxicity: A Systematic Review and Meta-Analysis. Therapeutic Drug Monitoring, 2023, 45, 519-532.	1.0	5
628	The Safety and Efficacy of AUC/MIC-Guided vs Trough-Guided Vancomycin Monitoring Among Veterans. , 2023, 40, .		0
629	Impact of Pharmacist-Led Multidisciplinary Team to Attain Targeted Vancomycin Area under the Curved Monitoring in a Tertiary Care Center in Thailand. Antibiotics, 2023, 12, 374.	1.5	1
630	Pharmacokinetics and Pharmacodynamics of a Novel Vancomycin Derivative LYSC98 in a Murine Thigh Infection Model Against Staphylococcus aureus. Infection and Drug Resistance, 0, Volume 16, 1019-1028.	1.1	4

#	Article	IF	Citations
631	What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value. Microorganisms, 2023, 11, 567.	1.6	1
632	Population pharmacokinetics of vancomycin in very low birth weight neonates. Frontiers in Pediatrics, 0, 11, .	0.9	4